Generalized anxiety disorder can remain difficult to manage even after medication, psychotherapy, or both. At The Mind Grove TMS Center in Colorado Springs, Dr. Bowers may consider rTMS for adults with GAD on an off-label basis. Because TMS is not FDA-cleared for GAD, we explain that distinction clearly before treatment is considered.
What Is Generalized Anxiety Disorder
Generalized anxiety disorder (GAD) is characterized by excessive, persistent worry that is difficult to control and interferes with daily functioning (Mayo Clinic, 2025). Symptoms include restlessness, muscle tension, difficulty concentrating, irritability, and sleep disturbances. The worry in GAD is not confined to a single concern or situation. It is broad, chronic, and often disproportionate to the circumstances that trigger it.
Standard first-line treatments for GAD include SSRIs, SNRIs, and specific forms of psychotherapy, particularly cognitive behavioral therapy (American Psychiatric Association, 2026). These approaches are effective for many patients. For adults whose GAD symptoms remain significant despite standard treatment, Dr. Bowers may consider rTMS on an off-label basis after clinical evaluation.
What Off-Label Means, and Why It Matters
TMS does not currently carry FDA clearance for generalized anxiety disorder. Offering rTMS for GAD is an off-label use, meaning the treatment is being applied to an indication outside the scope of its current FDA-cleared applications. Off-label means the FDA has not cleared TMS specifically for GAD. A physician may still consider an off-label treatment when clinical evaluation supports its use, but the evidence and insurance considerations differ from FDA-cleared indications.
What it means practically is this: TMS for GAD is generally not covered by insurance.. Patients pursuing rTMS for anxiety at The Mind Grove TMS Center should expect to discuss coverage and cost with our team before making any treatment decisions. The evidence base for TMS in GAD is still developing and is less established than the evidence for depression-related FDA-cleared indications.. We want patients to enter this process with accurate expectations about what the research currently supports.
What the Research Shows
The relationship between anxiety and depression is well-documented and clinically significant. TMS has an FDA-cleared indication for MDD with co-occurring anxiety symptoms (U.S. Food and Drug Administration, 2025). That is different from using TMS to treat primary GAD, which remains off-label. The distinction matters clinically and for insurance coverage.
The evidence specifically for rTMS in GAD is limited but developing. A 2022 systematic review and meta-analysis included six studies with 152 patients and found promising results, while emphasizing that the available studies were limited and heterogeneous and that more rigorous trials are needed (Parikh et al., 2022). Because TMS for GAD remains off-label, Dr. Bowers considers the available evidence alongside each patient’s diagnosis, treatment history, and clinical needs.
Patients with anxiety who are also experiencing depression may fall within the FDA-cleared population for TMS, particularly for MDD with co-occurring anxiety. That distinction matters both clinically and for insurance purposes, and it is worth discussing explicitly during the evaluation process.
Who Should Consider TMS for Anxiety
Dr. Bowers may consider off-label rTMS for adults with GAD who have not found adequate relief through standard treatment.
Because TMS for GAD is off-label, the evaluation process is especially important. Before treatment begins, Dr. Bowers reviews your diagnosis, treatment history, medications, and safety considerations to determine whether TMS is appropriate. Results vary by individual. We present rTMS for anxiety as a clinically informed option for the right patient, not as a guaranteed solution.
What to Expect from TMS for Anxiety at The Mind Grove TMS Center
Sessions are conducted in our Colorado Springs office with patients seated and fully awake. No anesthesia or sedation is required. A magnetic coil is positioned against the scalp and delivers pulses to the targeted brain region during each session. Common side effects can include headache and scalp or stimulation-site discomfort. These effects are generally acute and time-limited (Trapp et al., 2025).
Because TMS for GAD is off-label, the proposed treatment plan and how progress will be monitored are discussed during evaluation. TMS for primary GAD is generally not covered by insurance, so patients should discuss cost with our team before treatment begins.
FAQ
Is TMS approved for anxiety?
TMS does not currently carry FDA clearance for generalized anxiety disorder. At The Mind Grove TMS Center, Dr. Bowers may consider rTMS for adults with GAD on an off-label basis. TMS for primary GAD is generally not covered by insurance, and the evidence base is more limited than it is for FDA-cleared depression-related indications. MDD with co-occurring anxiety symptoms is a separate FDA-cleared indication and is evaluated differently.
Will insurance cover TMS for anxiety?
TMS for generalized anxiety disorder is an off-label use and is generally not covered by insurance for this indication. Insurance may cover qualifying FDA-cleared depression-related indications, including MDD with co-occurring anxiety symptoms, depending on the payer and medical-necessity criteria. Colorado Medicaid does not cover TMS. Our team can discuss cost and coverage considerations before treatment begins.
How is TMS for anxiety different from TMS for depression?
The main difference is the evidence and regulatory status. TMS has FDA-cleared depression-related indications, including MDD with co-occurring anxiety symptoms, while TMS for primary GAD remains off-label and is generally not covered by insurance. Dr. Bowers determines which diagnosis and treatment approach apply during clinical evaluation.
I have both anxiety and depression. Does that change my options?
Potentially, yes. If you have MDD with co-occurring anxiety symptoms, TMS may fall within an FDA-cleared indication. Insurance coverage still depends on your diagnosis, payer requirements, and medical-necessity criteria, so this is important to discuss during evaluation.
How long does TMS take to work for anxiety?
There is not one established response timeline for TMS in GAD, and its use for this condition remains off-label. The available research is still limited, so Dr. Bowers reviews treatment expectations and monitors each patient’s response throughout care (Parikh et al., 2022).
Key Takeaways
TMS for generalized anxiety disorder is offered at The Mind Grove TMS Center on an off-label basis; it does not carry FDA clearance for GAD and is generally not covered by insurance for this indication.
Evidence for rTMS in GAD is still limited. A systematic review and meta-analysis found promising results but emphasized the small, heterogeneous evidence base and the need for more rigorous trials (Parikh et al., 2022).
Patients with MDD and co-occurring anxiety symptoms may fall within an FDA-cleared indication for TMS.
TMS for primary GAD is generally not covered by insurance, so cost and coverage should be discussed before treatment begins.
Results vary by individual; a clinical evaluation determines whether rTMS may be appropriate for each patient before treatment begins.
If GAD symptoms remain significant after medication, psychotherapy, or both, Dr. Bowers may consider rTMS as an off-label option. She reviews your diagnosis, treatment history, current medications, and safety considerations before determining whether TMS is appropriate. Contact The Mind Grove TMS Center in Colorado Springs to learn more.
References
American Psychiatric Association. (2026). What are anxiety disorders?https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders
Parikh, T. K., Strawn, J. R., Walkup, J. T., & Croarkin, P. E. (2022). Repetitive transcranial magnetic stimulation for generalized anxiety disorder: A systematic literature review and meta-analysis. International Journal of Neuropsychopharmacology, 25(2), 144–146.https://pubmed.ncbi.nlm.nih.gov/34791241/
Trapp, N. T., Purgianto, A., Taylor, J. J., Singh, M. K., Oberman, L. M., Mickey, B. J., Youssef, N. A., Solzbacher, D., Zebley, B., Cabrera, L. Y., Conroy, S., Cristancho, M., Richards, J. R., Flood, M. J., Barbour, T., Blumberger, D. M., Taylor, S. F., Feifel, D., Reti, I. M., McClintock, S. M., Lisanby, S. H., & Husain, M. M. (2025). Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clinical Neurophysiology, 170, 206–233.https://pubmed.ncbi.nlm.nih.gov/39756350/
Mayo Clinic. (2025). Anxiety disorders: Symptoms and causes.https://www.mayoclinic.org/diseases-conditions/anxiety/symptoms-causes/syc-20350961
U.S. Food and Drug Administration. (2025). MagVenture TMS Therapy System (K251119).https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251119.pdf
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.